Fight Colorectal Cancer launches the Clinical Trials Webinar Series!
This first session, Understanding HER2: What Patients Need to Know, brings together leading experts and advocates to discuss HER2-positive metastatic colorectal cancer (mCRC) and emerging clinical trial opportunities — including insights from the MOUNTAINEER study.
You’ll learn:
- What HER2 means in colorectal cancer and how it’s tested
- Current HER2-targeted treatment approaches and research
- What patients should know when exploring clinical trials
- How advocacy and education drive access to biomarker testing
Panelist Speakers include Dr. Al B. Benson III (Professor of Medicine, Associate Director for Cooperative Groups, Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Dr. John Strickler (Professor of Medicine at Duke University -Co-Leader for the Precision Cancer Medicine and Investigational Therapeutics Program at the Duke Cancer Institute, Leader of the Molecular Tumor Board, and Associate Director of Clinical Research – GI Oncology, and Principal Investigator of MOUNTAINEER), and Daad Abighanem (Fight CRC dual Research Advocate and Ambassador).
This webinar is supported by Pfizer. Fight CRC independently develops and curates all content.
Fight Colorectal Cancer launches the Clinical Trials Webinar Series!
This first session, Understanding HER2: What Patients Need to Know, brings together leading experts and advocates to discuss HER2-positive metastatic colorectal cancer (mCRC) and emerging clinical trial opportunities — including insights from the MOUNTAINEER study.
You’ll learn:
- What HER2 means in colorectal cancer and how it’s tested
- Current HER2-targeted treatment approaches and research
- What patients should know when exploring clinical trials
- How advocacy and education drive access to biomarker testing
Panelist Speakers include Dr. Al B. Benson III (Professor of Medicine, Associate Director for Cooperative Groups, Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Dr. John Strickler (Professor of Medicine at Duke University -Co-Leader for the Precision Cancer Medicine and Investigational Therapeutics Program at the Duke Cancer Institute, Leader of the Molecular Tumor Board, and Associate Director of Clinical Research – GI Oncology, and Principal Investigator of MOUNTAINEER), and Daad Abighanem (Fight CRC dual Research Advocate and Ambassador).
This webinar is supported by Pfizer. Fight CRC independently develops and curates all content.
Fight Colorectal Cancer launches the Clinical Trials Webinar Series!
This first session, Understanding HER2: What Patients Need to Know, brings together leading experts and advocates to discuss HER2-positive metastatic colorectal cancer (mCRC) and emerging clinical trial opportunities — including insights from the MOUNTAINEER study.
You’ll learn:
- What HER2 means in colorectal cancer and how it’s tested
- Current HER2-targeted treatment approaches and research
- What patients should know when exploring clinical trials
- How advocacy and education drive access to biomarker testing
Panelist Speakers include Dr. Al B. Benson III (Professor of Medicine, Associate Director for Cooperative Groups, Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Dr. John Strickler (Professor of Medicine at Duke University -Co-Leader for the Precision Cancer Medicine and Investigational Therapeutics Program at the Duke Cancer Institute, Leader of the Molecular Tumor Board, and Associate Director of Clinical Research – GI Oncology, and Principal Investigator of MOUNTAINEER), and Daad Abighanem (Fight CRC dual Research Advocate and Ambassador).
This webinar is supported by Pfizer. Fight CRC independently develops and curates all content.
